Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
about
IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infectionHost immunity to Cryptococcus neoformansCryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortalityA peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in miceImproved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformansAntibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cellsThe absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs.Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected UgandansThe common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8.Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantationAntibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing.The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.New concepts in antibody-mediated immunity.IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.Human antibodies from transgenic animals.Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannanAntibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections.The capsule of the fungal pathogen Cryptococcus neoformans.Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis.Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections.Immunotherapy of Fungal Infections.The formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses.Immunotherapy against invasive fungal diseases in stem cell transplant recipients.
P2860
Q24631904-4D044C89-71C4-42CE-937B-B75836096843Q26823438-D4B2FAF2-1222-49BD-B9CA-0D9BAEBE1305Q30438524-0841E711-FE4F-45DC-8292-C73A3D1D84CFQ31137207-9A609E29-9163-4BE9-B2D2-C26D026A2E43Q33557968-494CFC7B-0F17-4296-93DE-AE8A77ECFB54Q33793546-3AE78EE3-BDF4-486D-826E-49EA80742285Q33912345-ACEE9C04-3A6D-402C-93BF-F72BE60C40D3Q34033551-324C9255-2ED5-45CA-BF8E-8531E633EDB5Q34072411-2794004E-FA38-4876-81E1-644062FA0E36Q34099803-EEEDFACA-FE88-43DE-80D6-E47347E58A9EQ34484101-B3BC2CE6-F913-4E6A-80E7-BA85132FEE02Q34720443-55091AA5-6334-43D0-A464-7C9F4CCE56EDQ35210328-FFB3BC1C-DD63-4F64-B95F-BE82E6E8F1F8Q35913526-364D5F54-BF4A-4B1F-8AFD-BD2CEAE6BBA8Q35926507-3EB1CEDD-9731-44EF-90D9-B2788454B9D7Q35952109-54E798D8-5870-4953-B256-F30ABB7F63A2Q36252986-4793EFF4-6A77-4B0A-8FB7-C5997275E12DQ36456615-9A5E8E77-3511-4B1E-8B76-25FF0BC46DC5Q36844895-7DBF237F-5EE8-4C08-BF0B-439C5E1D0A2BQ36914682-A321F19B-637E-4FED-BEA4-55468D086EFFQ36994373-63F3E490-0C9B-4C5F-9CBC-91BC076228F2Q37132306-0964148C-29A5-4B1A-BC17-E4DBAB0430A8Q37337879-F23A96C2-7885-4B03-B500-532D7896A45BQ37350575-BED0D940-A584-47BD-AE63-7726651FBEDCQ38067451-B9065627-1E66-44CA-9214-8FD0DBF4E2F4Q38635409-C3357272-80C7-4556-A53F-77601ECF1AF4Q41071866-87BC8524-5E3C-42C4-9711-B4C8F7D3DE00Q53152606-58795688-8404-4EF0-A220-1B20A13C34CF
P2860
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Protective and nonprotective h ...... icities and gene use profiles.
@ast
Protective and nonprotective h ...... icities and gene use profiles.
@en
type
label
Protective and nonprotective h ...... icities and gene use profiles.
@ast
Protective and nonprotective h ...... icities and gene use profiles.
@en
prefLabel
Protective and nonprotective h ...... icities and gene use profiles.
@ast
Protective and nonprotective h ...... icities and gene use profiles.
@en
P2093
P2860
P1476
Protective and nonprotective h ...... icities and gene use profiles.
@en
P2093
Bradley Witover
Kausik Datta
Krishanthi Subramaniam
Qing Chang
Robert W Maitta
Robin X Luo
P2860
P304
P356
10.1128/IAI.72.8.4810-4818.2004
P407
P577
2004-08-01T00:00:00Z